{"id":417661,"date":"2021-01-20T08:03:17","date_gmt":"2021-01-20T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=417661"},"modified":"2021-01-20T08:03:17","modified_gmt":"2021-01-20T13:03:17","slug":"gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/","title":{"rendered":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine"},"content":{"rendered":"
\n

\n \u2014 Deal provides nonexclusive access\u00a0to Genevant\u2019s leading LNP technology for use in Gritstone\u2019s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 <\/em>
\n \u2014<\/em>
\n \n <\/p>\n

\n \u2014 Agreement is the second between the parties since October 2020 \u2014<\/em>
\n \n <\/p>\n

EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry\u2019s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to which Gritstone has obtained a nonexclusive license to Genevant\u2019s LNP technology to develop and commercialize self-amplifying RNA (SAM) vaccines against SARS-CoV-2, the virus that causes COVID-19. Genevant\u2019s LNP platform is clinically validated and part of Gritstone\u2019s SAM neoantigen-based cancer immunotherapy now in Phase 2 testing.<\/p>\n

\u201cWe are pleased to extend our longstanding and productive collaboration with the Genevant team to include our newly launched COVID-19 program,\u201d said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. \u201cAs we continue to see new strains of SARS-CoV-2 emerge, we identified an opportunity to apply our key strengths to an innovative COVID-19 vaccine. Specifically, extending the antigenic content of a COVID-19 vaccine beyond Spike alone may open up a route to clinical protection even if Spike mutations reduce antibody binding. We believe our approach could make an important impact on COVID-19 by eliciting robust neutralizing antibody responses and plentiful anti-viral CD8+ T cells to both Spike and other key viral antigens.\u201d<\/p>\n

\u201cOptimized LNP characteristics can provide substantial advantages in safety, efficacy and pharmaceutical profiles, and Genevant scientists have been leaders in the field for two decades,\u201d said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation. \u201cWe are delighted to be able to expand our existing relationship with Gritstone to combine our industry-leading LNP technology with its innovative approach to help eliminate COVID-19.\u201d<\/p>\n

Under the terms of the agreement, Genevant is eligible to receive from Gritstone up to $192 million in upfront and contingent milestone payments per product, plus royalties ranging from the mid-single to the mid-double digits on future product sales. In the event that Gritstone outlicenses the COVID-19 program, Genevant may in certain circumstances be entitled to a percentage of amounts that Gritstone receives.<\/p>\n

\n About Gritstone Oncology<\/strong>
\n
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars\u2014first, a proprietary machine learning-based platform, Gritstone EDGETM<\/sup>, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient\u2019s immune system to specifically attack and destroy disease-causing cells. The company\u2019s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an \u201coff the shelf\u201d shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine with support from departments within the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation and a license agreement with La Jolla Institute for Immunology. For more information, please visit gritstoneoncology.com<\/a>.<\/p>\n

\n About Genevant Sciences<\/strong>
\n
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industry\u2019s most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development. The Company\u2019s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company\u2019s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit\u00a0www.genevant.com<\/a>.<\/p>\n

\n Gritstone Forward-Looking <\/strong>
\n Statements<\/strong>
\n
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone\u2019s therapeutic program in COVID-19. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone\u2019s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone\u2019s programs\u2019 early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone\u2019s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone\u2019s most recent Quarterly Report on Form 10-Q filed on November 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.<\/p>\n

\n
\n Gritstone Contacts<\/u>
\n <\/strong>
\n
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com<\/a><\/p>\n

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014 Deal provides nonexclusive access\u00a0to Genevant\u2019s leading LNP technology for use in Gritstone\u2019s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 \u2014 \u2014 Agreement is the second between the parties since October 2020 \u2014 EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry\u2019s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to which Gritstone has obtained a nonexclusive license to Genevant\u2019s LNP technology to develop and … <\/p>\n

Continue reading “Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-417661","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2014 Deal provides nonexclusive access\u00a0to Genevant\u2019s leading LNP technology for use in Gritstone\u2019s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 \u2014 \u2014 Agreement is the second between the parties since October 2020 \u2014 EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry\u2019s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to which Gritstone has obtained a nonexclusive license to Genevant\u2019s LNP technology to develop and … Continue reading "Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine\",\"datePublished\":\"2021-01-20T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/\"},\"wordCount\":934,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/\",\"name\":\"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=\",\"datePublished\":\"2021-01-20T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk","og_description":"\u2014 Deal provides nonexclusive access\u00a0to Genevant\u2019s leading LNP technology for use in Gritstone\u2019s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 \u2014 \u2014 Agreement is the second between the parties since October 2020 \u2014 EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry\u2019s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to which Gritstone has obtained a nonexclusive license to Genevant\u2019s LNP technology to develop and … Continue reading \"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-20T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine","datePublished":"2021-01-20T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/"},"wordCount":934,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/","name":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=","datePublished":"2021-01-20T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE2NiMzOTM1NTE4IzIxMjM1MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gritstone-and-genevant-sciences-announce-license-agreement-for-covid-19-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=417661"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417661\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=417661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=417661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=417661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}